111 related articles for article (PubMed ID: 11312923)
1. Synthesis and biological activity of aminoguanidine and diaminoguanidine analogues of the antidiabetic/antiobesity agent 3-guanidinopropionic acid.
Vaillancourt VA; Larsen SD; Tanis SP; Burr JE; Connell MA; Cudahy MM; Evans BR; Fisher PV; May PD; Meglasson MD; Robinson DD; Stevens FC; Tucker JA; Vidmar TJ; Yu JH
J Med Chem; 2001 Apr; 44(8):1231-48. PubMed ID: 11312923
[TBL] [Abstract][Full Text] [Related]
2. Synthesis and biological activity of analogues of the antidiabetic/antiobesity agent 3-guanidinopropionic acid: discovery of a novel aminoguanidinoacetic acid antidiabetic agent.
Larsen SD; Connell MA; Cudahy MM; Evans BR; May PD; Meglasson MD; O'Sullivan TJ; Schostarez HJ; Sih JC; Stevens FC; Tanis SP; Tegley CM; Tucker JA; Vaillancourt VA; Vidmar TJ; Watt W; Yu JH
J Med Chem; 2001 Apr; 44(8):1217-30. PubMed ID: 11312922
[TBL] [Abstract][Full Text] [Related]
3. Antihyperglycemic action of guanidinoalkanoic acids: 3-guanidinopropionic acid ameliorates hyperglycemia in diabetic KKAy and C57BL6Job/ob mice and increases glucose disappearance in rhesus monkeys.
Meglasson MD; Wilson JM; Yu JH; Robinson DD; Wyse BM; de Souza CJ
J Pharmacol Exp Ther; 1993 Sep; 266(3):1454-62. PubMed ID: 8371149
[TBL] [Abstract][Full Text] [Related]
4. Antidiabetic activity of perylenequinonoid-rich extract from Shiraia bambusicola in KK-Ay mice with spontaneous type 2 diabetes mellitus.
Huang M; Zhao P; Xiong M; Zhou Q; Zheng S; Ma X; Xu C; Yang J; Yang X; Zhang TC
J Ethnopharmacol; 2016 Sep; 191():71-81. PubMed ID: 27286915
[TBL] [Abstract][Full Text] [Related]
5. Synthesis and evaluation of quinoline carboxyguanidines as antidiabetic agents.
Edmont D; Rocher R; Plisson C; Chenault J
Bioorg Med Chem Lett; 2000 Aug; 10(16):1831-4. PubMed ID: 10969979
[TBL] [Abstract][Full Text] [Related]
6. Design, synthesis, and biological evaluation of substituted-N-(thieno[2,3-b]pyridin-3-yl)-guanidines, N-(1H-pyrrolo[2,3-b]pyridin-3-yl)-guanidines, and N-(1H-indol-3-yl)-guanidines.
Bahekar RH; Jain MR; Goel A; Patel DN; Prajapati VM; Gupta AA; Jadav PA; Patel PR
Bioorg Med Chem; 2007 May; 15(9):3248-65. PubMed ID: 17339113
[TBL] [Abstract][Full Text] [Related]
7. Characterization of new oral antidiabetic agent CS-045. Studies in KK and ob/ob mice and Zucker fatty rats.
Fujiwara T; Yoshioka S; Yoshioka T; Ushiyama I; Horikoshi H
Diabetes; 1988 Nov; 37(11):1549-58. PubMed ID: 3053303
[TBL] [Abstract][Full Text] [Related]
8. The effect of 1,3-diaryl-[1H]-pyrazole-4-acetamides on glucose utilization in ob/ob mice.
Bebernitz GR; Argentieri G; Battle B; Brennan C; Balkan B; Burkey BF; Eckhardt M; Gao J; Kapa P; Strohschein RJ; Schuster HF; Wilson M; Xu DD
J Med Chem; 2001 Aug; 44(16):2601-11. PubMed ID: 11472214
[TBL] [Abstract][Full Text] [Related]
9. Improved stability, insulin-releasing activity and antidiabetic potential of two novel N-terminal analogues of gastric inhibitory polypeptide: N-acetyl-GIP and pGlu-GIP.
O'Harte FP; Gault VA; Parker JC; Harriott P; Mooney MH; Bailey CJ; Flatt PR
Diabetologia; 2002 Sep; 45(9):1281-91. PubMed ID: 12242461
[TBL] [Abstract][Full Text] [Related]
10. Repeat treatment of obese mice with BRL 49653, a new potent insulin sensitizer, enhances insulin action in white adipocytes. Association with increased insulin binding and cell-surface GLUT4 as measured by photoaffinity labeling.
Young PW; Cawthorne MA; Coyle PJ; Holder JC; Holman GD; Kozka IJ; Kirkham DM; Lister CA; Smith SA
Diabetes; 1995 Sep; 44(9):1087-92. PubMed ID: 7657033
[TBL] [Abstract][Full Text] [Related]
11. Eburicoic Acid, a Triterpenoid Compound from Antrodia camphorata, Displays Antidiabetic and Antihyperlipidemic Effects in Palmitate-Treated C2C12 Myotubes and in High-Fat Diet-Fed Mice.
Lin CH; Kuo YH; Shih CC
Int J Mol Sci; 2017 Nov; 18(11):. PubMed ID: 29099085
[TBL] [Abstract][Full Text] [Related]
12. Discovery of cyclic guanidines as potent, orally active, human glucagon receptor antagonists.
Sinz C; Chang J; Lins AR; Brady E; Candelore M; Dallas-Yang Q; Ding V; Jiang G; Lin Z; Mock S; Qureshi S; Salituro G; Saperstein R; Shang J; Szalkowski D; Tota L; Vincent S; Wright M; Xu S; Yang X; Zhang B; Tata J; Kim R; Parmee E
Bioorg Med Chem Lett; 2011 Dec; 21(23):7131-6. PubMed ID: 22001094
[TBL] [Abstract][Full Text] [Related]
13. GIP(Lys16PAL) and GIP(Lys37PAL): novel long-acting acylated analogues of glucose-dependent insulinotropic polypeptide with improved antidiabetic potential.
Irwin N; O'Harte FP; Gault VA; Green BD; Greer B; Harriott P; Bailey CJ; Flatt PR
J Med Chem; 2006 Feb; 49(3):1047-54. PubMed ID: 16451070
[TBL] [Abstract][Full Text] [Related]
14. Inhibition of dipeptidyl peptidase-IV activity by metformin enhances the antidiabetic effects of glucagon-like peptide-1.
Green BD; Irwin N; Duffy NA; Gault VA; O'harte FP; Flatt PR
Eur J Pharmacol; 2006 Oct; 547(1-3):192-9. PubMed ID: 16945366
[TBL] [Abstract][Full Text] [Related]
15. The effect of the creatine analogue beta-guanidinopropionic acid on energy metabolism: a systematic review.
Oudman I; Clark JF; Brewster LM
PLoS One; 2013; 8(1):e52879. PubMed ID: 23326362
[TBL] [Abstract][Full Text] [Related]
16. Development of a liver-targeted stearoyl-CoA desaturase (SCD) inhibitor (MK-8245) to establish a therapeutic window for the treatment of diabetes and dyslipidemia.
Oballa RM; Belair L; Black WC; Bleasby K; Chan CC; Desroches C; Du X; Gordon R; Guay J; Guiral S; Hafey MJ; Hamelin E; Huang Z; Kennedy B; Lachance N; Landry F; Li CS; Mancini J; Normandin D; Pocai A; Powell DA; Ramtohul YK; Skorey K; Sørensen D; Sturkenboom W; Styhler A; Waddleton DM; Wang H; Wong S; Xu L; Zhang L
J Med Chem; 2011 Jul; 54(14):5082-96. PubMed ID: 21661758
[TBL] [Abstract][Full Text] [Related]
17. Evaluation of the antidiabetic activity of DPP IV resistant N-terminally modified versus mid-chain acylated analogues of glucose-dependent insulinotropic polypeptide.
Irwin N; Clarke GC; Green BD; Greer B; Harriott P; Gault VA; O'Harte FP; Flatt PR
Biochem Pharmacol; 2006 Sep; 72(6):719-28. PubMed ID: 16859646
[TBL] [Abstract][Full Text] [Related]
18. Effects of antidiabetic drugs on dipeptidyl peptidase IV activity: nateglinide is an inhibitor of DPP IV and augments the antidiabetic activity of glucagon-like peptide-1.
Duffy NA; Green BD; Irwin N; Gault VA; McKillop AM; O'Harte FP; Flatt PR
Eur J Pharmacol; 2007 Jul; 568(1-3):278-86. PubMed ID: 17573070
[TBL] [Abstract][Full Text] [Related]
19. Acute intravenous leptin infusion increases glucose turnover but not skeletal muscle glucose uptake in ob/ob mice.
Burcelin R; Kamohara S; Li J; Tannenbaum GS; Charron MJ; Friedman JM
Diabetes; 1999 Jun; 48(6):1264-9. PubMed ID: 10342814
[TBL] [Abstract][Full Text] [Related]
20. Antidiabetic effects of the Cimicifuga racemosa extract Ze 450 in vitro and in vivo in ob/ob mice.
Moser C; Vickers SP; Brammer R; Cheetham SC; Drewe J
Phytomedicine; 2014 Sep; 21(11):1382-9. PubMed ID: 25022210
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
